Table of Contents

• What is ZIRCONIUM (89ZR) CREFMIRLIMAB BERDOXAM?
• How does it work?
• What is it used for?
• How is it administered?
• Potential side effects
• Ongoing research

What is ZIRCONIUM (89ZR) CREFMIRLIMAB BERDOXAM?

ZIRCONIUM (89ZR) CREFMIRLIMAB BERDOXAM is an innovative imaging agent used in positron emission tomography (PET) scans. It is also known by several other names, including:

• Zirconium Zr 89 crefmirlimab berdoxam
• 89Zr-Df-IAB22M2C
• 89Zr-desferrioxamine-IAB22M2C
• RO7499775

How does it work?

ZIRCONIUM (89ZR) CREFMIRLIMAB BERDOXAM works by targeting and attaching to CD8+ T cells in the body. CD8+ T cells are a type of immune cell that plays a crucial role in fighting cancer and infections. The zirconium-89 component of the compound emits a small amount of radiation that can be detected by a PET scanner, allowing doctors to see where these important immune cells are located in the body^[1].

What is it used for?

This imaging agent is being studied for use in several medical conditions:

1. Cancer: It can help doctors visualize how the immune system is responding to cancer, particularly in patients receiving immunotherapy treatments. This includes:
   • Non-small cell lung cancer
   • Metastatic melanoma (skin cancer that has spread)
   • Other solid tumors
2. Inflammatory diseases:
   • Rheumatoid arthritis (a condition causing joint inflammation)
   • Giant cell arteritis (inflammation of blood vessels, typically in the head)

By showing where CD8+ T cells are concentrated, this imaging technique can help doctors:

• Assess how well cancer treatments are working
• Predict which patients might respond best to certain therapies
• Detect early signs of side effects from immunotherapy
• Monitor inflammation in autoimmune diseases

How is it administered?

ZIRCONIUM (89ZR) CREFMIRLIMAB BERDOXAM is given as an intravenous injection or infusion. This means it is delivered directly into a vein. The dose is typically measured in megabecquerels (MBq), which is a unit used to measure radioactivity. After receiving the injection, patients undergo a PET/CT scan, usually within a few hours to a few days^[1][4].

Potential side effects

As ZIRCONIUM (89ZR) CREFMIRLIMAB BERDOXAM is a diagnostic agent used in very small quantities, severe side effects are rare. However, potential risks may include:

• Allergic reactions to the compound
• Mild discomfort at the injection site
• Exposure to a small amount of radiation (less than many standard medical imaging procedures)

Ongoing research

Several clinical trials are currently underway to further investigate the uses of ZIRCONIUM (89ZR) CREFMIRLIMAB BERDOXAM:

• A study comparing it to another imaging agent in non-small cell lung cancer patients receiving immunotherapy^[1]
• Research on its ability to detect early signs of side effects in melanoma patients receiving immune checkpoint inhibitor therapy^[3]
• Investigations into its use for imaging inflammation in rheumatoid arthritis and giant cell arteritis^[2]
• A study examining its effectiveness in predicting treatment response in various solid tumors^[4]